Cipla Ltd
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Cipla Ltd's management has expressed a confident outlook, emphasizing a strategic shift towards high-value chronic therapies in India and a robust product pipeline in the U.S. Despite facing near-term earnings pressure due to inventory charges and regulatory challenges, management anticipates a recovery in margins as new product launches gain traction. Vista's financial outlook reflects this optimism, projecting a gradual revenue recovery supported by Cipla's focus on complex generics and specialty therapies, particularly in the respiratory segment. The expected annualized sales run-rate of USD 1 billion in FY27 underscores the potential for growth, although challenges such as pricing pressures in the U.S. and competition in the biosimilars market remain pertinent. The favorable currency dynamics and resilient demand for chronic therapies provide additional tailwinds. Over the next 12-24 months, key opportunities include successful product launches and market expansion, while watchpoints include regulatory timelines and the impact of geopolitical tensions on supply chains
Why We Like This Stock
- Management's focus on high-value chronic therapies and a strong U.S. product pipeline is expected to drive future revenue growth
- Cipla's anticipated annualized sales run-rate of USD 1 billion in FY27 highlights significant growth potential
- Favorable currency dynamics and resilient demand in chronic therapies are expected to support revenue stability
Things To Watch Out For
- Near-term earnings pressure due to inventory charges and regulatory challenges may impact margins
- Pricing pressures in the U.S. market could hinder revenue growth and profitability
- Increased competition in the biosimilars space poses risks to Cipla's market share and margins
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 25,774 | 27,548 | 28,163 | 28,356 | 31,353 |
| Profit Before Tax (Cr.) | 5,824 | 6,652 | 5,500 | 4,695 | 5,888 |
| PBT Margin | 22.6% | 24.1% | 19.5% | 16.6% | 18.8% |
| Net Profit (Cr.) | 4,090 | 4,963 | 3,975 | 3,396 | 4,241 |
| Earnings Per Share | 50.2 | 61.5 | 49.4 | 41.8 | 52.5 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Macguire | ▲ Buy | 1,675 | 11-Sep-2026 |
| Morgan Stanley | ▼ Underweight | 1,218 | 02-Sep-2026 |
| Citigroup | ▲ Buy | 1,700 | 26-Aug-2026 |
| JPMorgan | ▲ Overweight | 1,600 | 29-Jul-2026 |
| Kotak Securities | ▲ Buy | 1,675 | 29-Jul-2026 |
| Goldman Sachs | ► Hold | 1,375 | 24-Jul-2026 |
| ICICI Securities | ▲ Buy | 1,610 | 24-Jul-2026 |
| Jeffries | ▼ Underperform | 1,170 | 24-Jul-2026 |
| Motilal Oswal | ► Neutral | 1,420 | 24-Jul-2026 |
| Nomura | ▲ Buy | 1,510 | 24-Jul-2026 |
| Prabhudas Liladhar | ► Accumulate | 1,450 | 24-Jul-2026 |
| BPWealth | ▲ Buy | 1,714 | 10-Jul-2026 |
| JMFinancials | ▲ Buy | 1,546 | 15-May-2026 |
| BOB Capital Markets | ► Hold | 1,378 | 14-May-2026 |
| Equirus Securities | ▲ Buy | 1,555 | 14-May-2026 |
| HSBC | ► Hold | 1,340 | 14-May-2026 |
| Moneycontrol | ▲ Overweight | nan | 14-May-2026 |
| Nuvama | ► Hold | 1,460 | 14-May-2026 |
| Elara Capital | ► Accumulate | 1,438 | 23-Apr-2026 |
Company Overview
Show Company Profile
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.